Philippe Alexandre Gilbert | Senior Scientist, Cell Culture Development, Research and Development
Glaxosmithkline Biologicals Sa

Philippe Alexandre Gilbert, Senior Scientist, Glaxosmithkline Biologicals Sa

Born in Quebec City (Canada), Dr. Philippe-Alexandre Gilbert is a graduate of the department of biochemistry at the University of Ottawa . He pursued his education at Laval University where he obtained his masters degree in molecular biology and his doctorate in biochemical engineering. For over 14 years now Dr. Gilbert has built a solid expertise in molecular design and development of bioprocesses for gene therapy vectors, oncolytic viruses and vaccines. He had the privilege of working for organizations such as the Biotechnology Research Institute(CNRC), the Robarts Research institute (Western Ontario University), the Emerging Pathogen Institute (University of Florida) and in the private sector with Sanofi-Pasteur, Wellstat Biologics and MedImmune (Astra Zeneca). He has lead task force teams for SARS, HIV, RSV and Pandemic H1N1 Influenza. Dr. Gilbert has recently joined the cell culture department at GSK Biologicals and continues to focus his efforts on new cell culture technology. Dr. Gilbert is the proud father of three children and resides with his family in Belgium.

Share this

Appearances at this years' conference:

Day 3 - Thursday 1st March 2012


@ 10.30
Panel discussion: delivering a robust, yet flexible upstream process

  • Can the upstream processes become reproducible and efficient by utilising currently available bioreactor technologies?
  • Highlighting the challenges of process scale-up, and identifying future strategies to deliver a reproducible production cycle
  • What abilities does the next generation of bioreactor require if the cell culture industry is to continue to grow?

  • › Philippe Alexandre Gilbert, Senior Scientist, Cell Culture Development, Research and Development, Glaxosmithkline Biologicals Sa

DAY 2 - Wednesday 29th February 2012


@ 16.40
Can single-use bioreactors be implemented in vaccine production?

  • Evaluating the significant benefits of disposable technologies in this role from reducing investments costs to increasing facility output  
  • Understanding the challenges which need to be overcome due to biosafety, and the need for multiple cell lines increasing the complexity of platform technology
  • Should viral vaccine production be carried out in disposable technologies or are the association difficulties too great?

  • › Philippe Alexandre Gilbert, Senior Scientist, Cell Culture Development, Research and Development, Glaxosmithkline Biologicals Sa
Sponsors
Gold & Lunch Sponsor
Irvine Scientific at Cell Culture World Congress 2012
Gold Sponsor
BD Biosciences at Cell Culture World Congress 2012
Gold Sponsor
Cevec Pharmaceuticals GmbH at Cell Culture World Congress 2012
Gold Sponsor
PAA Labs at Cell Culture World Congress 2012
Gold Sponsor
Catalent Pharma Solutions at Cell Culture World Congress 2012
Gold Sponsor
Merck KGaA at Cell Culture World Congress 2012
Gold Sponsor
Life Technologies at Cell Culture World Congress 2012
Drinks Reception Sponsor
Lonza at Cell Culture World Congress 2012
Associate Sponsor
Roche Diagnostics GmbH at Cell Culture World Congress 2012
Associate Sponsor
GE Healthcare at Cell Culture World Congress 2012
Associate Sponsor
Leica Microsystems at Cell Culture World Congress 2012
Associate Sponsor
Metabolon Inc at Cell Culture World Congress 2012
Associate Sponsor
Metanomics Health GmbH at Cell Culture World Congress 2012
Associate Sponsor
SAFC at Cell Culture World Congress 2012
Exhibitor
Bayer Technology Services GmbH at Cell Culture World Congress 2012
Exhibitor
VIVALIS SA at Cell Culture World Congress 2012
Exhibitor
Caridian BCT at Cell Culture World Congress 2012
Exhibitor
Wuhan Healthgen Biotechnology Co. Ltd at Cell Culture World Congress 2012
Exhibitor
Nova Biomedical at Cell Culture World Congress 2012
Literature Sponsor
SciLog Inc at Cell Culture World Congress 2012
Literature Sponsor
CerCell Aps at Cell Culture World Congress 2012